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Abstract: Research in recent years on peroxisome proliferator-activated receptor (PPAR)β/δ indicates
that it plays a key role in the maintenance of energy homeostasis, both at the cellular level and within
the organism as a whole. PPARβ/δ activation might help prevent the development of metabolic
disorders, including obesity, dyslipidaemia, type 2 diabetes mellitus and non-alcoholic fatty liver
disease. This review highlights research findings on the PPARβ/δ regulation of energy metabolism
and the development of diseases related to altered cellular and body metabolism. It also describes the
potential of the pharmacological activation of PPARβ/δ as a treatment for human metabolic disorders.
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1. Introduction
Acquired metabolic disorders, particularly obesity and its associated co-morbidities currently
pose a risk to human health on a global scale. These metabolic disorders are closely related to adipose
tissue dysfunction, one of the primary defects observed in obesity that may link this condition to
its co-morbidities such as non-alcoholic fatty liver disease (NAFLD), atherogenic dyslipidaemia,
type 2 diabetes mellitus and cardiovascular disease [1–3]. In fact, up to a third of obese subjects are
metabolically healthy and they do not develop obesity-related metabolic or cardiovascular disorders [4],
probably because of the preservation of normal adipose tissue architecture and function. Adipose
tissue dysfunction in obese patients results from the interactions of genetic and environmental factors
that lead to the presence of hypertrophic adipocytes, which have a pro-inflammatory, insulin-resistant
phenotype compared to small adipocytes [5]. In addition, a critical factor contributing to the difference
between metabolically healthy and unhealthy obese individuals is the anatomical distribution of
the adipose tissues. Expansion of the visceral adipose tissue, which is considered a dysfunctional
adipose tissue unable to store excessive levels of lipids, to a greater extent than that of subcutaneous
adipose tissue, is associated with metabolic alterations [6]. Failure to store surplus lipids into visceral
adipose tissue causes a chronic elevation of circulating fatty acids (FA), which can reach toxic levels in
non-adipose tissues, such as skeletal muscle, the liver and the pancreas [7]. The deleterious effect of
lipid accumulation in non-adipose tissues is known as lipotoxicity. This surplus of fatty acids (FAs),
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especially saturated FA and their derived metabolites, such as diacylglycerol and ceramides, induces
chronic low-grade inflammation and has harmful effects on multiple organs and systems.
Given the enormous stress on global health services caused by the increasing incidence of obesity
and its co-morbidities on global health services, there is a need to better understand the mechanisms
behind the relationship between obesity and the development of metabolic disorders to prevent and
to improve the outcomes of these diseases. Peroxisome proliferator-activated receptor (PPAR)β/δ
is a nuclear receptor that exerts many metabolic effects. Its activation may prevent and improve the
outcome of obesity-related metabolic disorders. In this review, we will summarize the molecular
features of PPARβ/δ and the benefits of using its agonists to treat obesity and its related co-morbidities.
2. Basic Overview of the Molecular Features of PPARβ/δ
PPARβ/δ is a member of the nuclear receptor (NR) superfamily of ligand-inducible transcription
factors and belongs to the PPAR family, which comprises three isotypes: PPARα (NR1C1, according
to the unified nomenclature system for the NR superfamily); PPARβ/δ (NR1C2); and PPARγ
(NR1C3) [8,9]. PPARβ/δ was initially called PPARβ when it was first cloned in Xenopus laevis.
However, when cloned in other species it was not clearly identified as being homologous to the
Xenopus PPARβ and it was alternatively called NUC-1 in humans and PPARδ in mice. Currently,
it is accepted that Xenopus PPARβ is homologous to murine PPARδ, giving rise to the terminology
PPARβ/δ [8]. PPARβ/δ consists of four major functional domains: The N-terminal ligand-independent
transactivation domain (A/B domain), often known as activation function 1 (AF-1); the DNA binding
domain (DBD or C domain); the hinge region (D domain); and the carboxy-terminal E domain or AF-2,
which includes the ligand-binding domain and the ligand-dependent transactivation domain [8,9].
The major physiological functions of PPARβ/δ result from its activity as a transcription factor,
modulating the expression of specific target genes. Through this mechanism, PPARβ/δ regulates lipid
metabolism and glucose homeostasis [8–11]. In addition, PPARβ/δ can regulate inflammation [12].
The involvement of PPARβ/δ in all these functions depends on its tissue distribution, ligand binding
and the recruitment of co-activators or co-repressors.
PPARβ/δ is ubiquitously expressed, although it is most abundant in metabolically active tissues,
especially in those organs/cells associated with FA metabolism, such as skeletal and cardiac muscle,
hepatocytes and adipocytes. It has also been particularly characterized in macrophages. Compared to
other NRs, PPARs present a large ligand-binding pocket (≈1300 Å3) [8], which directly contributes to
the ability of PPARs to bind a great variety of endogenous and synthetic ligands. FAs are considered
endogenous PPAR ligands but they show little selectivity for the different PPAR isoforms. Although
all-trans retinoic acid has been reported to be a PPARβ/δ agonist [13], this has not been confirmed
by other groups [14,15] and therefore remains controversial. To elucidate PPARβ/δ functions,
synthetic ligands with high affinity and specificity (GW501516, GW0742 and L-165041) that only
activate PPARβ/δ at very low concentrations both in vivo and in vitro have been developed [8].
At present, there are no clinically available drugs targeting PPARβ/δ but three PPARβ/δ agonists have
reached clinical trials: Seladelpar (MBX-8025) (CymaBay Therapeutics) [16]; KD-3010 (Kalypsys) [17];
and CER-002 (Cerenis).
To activate transcription, PPARβ/δ forms an obligate heterodimer with retinoid X receptor (RXR or
NR2B) and binds to peroxisome proliferator response elements (PPREs) located at the promoter regions
of target genes, thereby increasing gene transcription in a ligand-dependent manner (transactivation) [8].
In the absence of a ligand, the PPARβ/δ-RXR heterodimer is bound by nuclear co-repressor proteins,
which block transcriptional activation by preventing the binding of the heterodimer to the promoter.
Ligand binding induces a conformational change within PPARβ/δ, resulting in the dissociation of the
co-repressors and the recruitment of co-activators, which subsequently lead to PPARβ/δ-RXR binding
to PPREs to initiate transcription [8]. PPARβ/δ also regulates gene expression independently of DNA
binding, via cross-talk with other types of transcription factors, thus influencing their function through
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a mechanism termed receptor-dependent transrepression [8]. Most of the anti-inflammatory effects of
PPARs probably occur through this mechanism [12].
3. PPARβ/δ as a Major Regulator of Metabolic Disorders
3.1. Obesity
PPARβ/δ-deficient mice exhibited a marked reduction in adiposity compared to wild-type mice
levels [18]. This effect, however, cannot be reproduced in mice harbouring an adipose tissue-specific
deletion of PPARβ/δ, indicating that PPARβ/δ elicits peripheral functions in systemic lipid metabolism.
In fact, PPARβ/δ activation prevents weight gain in diet- or genetically-induced animal models of
obesity by increasing fat burning in different tissues [19,20] or switching muscle fibre type, which,
in turn, increases the muscle oxidative capacity [21] (Figure 1). A recent study also suggests that
intestinal PPARβ/δ protects against diet-induced obesity, since intestinal epithelial cell-specific deletion
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Figure  1. PPARβ/δ  activation prevents  obesity  through  several mechanisms. PPARβ/δ  activation 
reduces  pre‐adipocyte  proliferation  and  differentiation,  attenuates  angiotensin  II‐mediated 





since  PPARβ/δ  also  regulates  preadipocyte  proliferation  and  differentiation  through  different 
mechanisms [23–25], such as by regulating of the expression of PPARγ, a key regulator of terminal 
adipocyte  differentiation. Moreover,  PPARβ/δ  ligands  prevent  angiotensin  II‐induced  adipocyte 
growth  and  lipid  accumulation  [26]. Angiotensin  II  increases  levels  of  reactive  oxygen  species 
(ROS),  which  attenuate  the  canonical  Wnt  signalling  pathway,  leading  to  dysfunctional 
hypertrophic  adipogenesis. PPARβ/δ  agonists prevent oxidative  stress  and  the  reduction  in Wnt 
signalling pathway induced by angiotensin II by increasing the expression of heme oxygenase 1 in 
Figure 1. PPARβ/δ activation prevents obesity through several mechanisms. PPARβ/δ activation
reduces pre-adipocyte proliferation and differentiation, attenuates angiotensin II-mediated dysfunctional
hypertrophic adipogenesis and inhibits inflammation in adipose tissue. PPARβ/δ ligands reduce the
availability of fatty acids to be stored in adipose tissue since these drugs induce fat burn in skeletal muscle
by either increasing fatty acid oxidation or switching muscle fibre type towards oxidative metabolism.
Blue arrow: increases. Red arrow: decreases.
Additional PPARβ/δ-mediated mechanisms can also contribute to the reduction in adiposity,
since PPARβ/δ also regulates preadipocyte proliferation and differentiation through different
mechanisms [23–25], such as by regulating of the expression of PPARγ, a key regulator of terminal
adipocyte differentiation. Moreover, PPARβ/δ ligands prevent angiotensin II-induced adipocyte
growth and lipid accumulation [26]. Angiotensin II increases levels of reactive oxygen species
(ROS), which attenuate the canonical Wnt signalling pathway, leading to dysfunctional hypertrophic
adipogenesis. PPARβ/δ agonists prevent oxidative stress and the reduction in Wnt signalling pathway
induced by angiotensin II by increasing the expression of heme oxygenase 1 in adipose tissue.
Consequently, PPARβ/δ activation delays preadipocyte maturation and lipid accumulation, leading
to increased numbers of smaller adipocytes with an improved adipocytokine profile. Thus, overall,
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PPARβ/δ activation prevents oxidative stress and dysfunctional adipogenesis under conditions of
overactive renin-angiotensin system [26].
In humans, PPARβ/δ expression is reduced in both the subcutaneous and in visceral adipose
tissues of morbidly obese patients compared to non-obese subjects [27]. This might result in adipose
tissue dysregulation since PPARβ/δ has anti-inflammatory effects in white adipose tissue. PPARβ/δ
activation inhibits lipopolysaccharide (LPS)-induced cytokine expression and secretion by preventing
nuclear factor (NF)-κB activation in adipocytes via the activation of mitogen-activated protein kinase
(MAPK)–extracellular signal-regulated kinase (ERK)1/2 (MEK1/2) activation [28]. Furthermore,
adipose tissue inflammation is characterized by increased infiltration and an altered polarization of the
macrophages from the anti-inflammatory M2 phenotype towards the pro-inflammatory M1 phenotype,
with PPARβ/δ a crucial signalling molecule that activates polarization towards the anti-inflammatory
M2 phenotype [29]. Consistent with the effects of PPARβ/δ in adipose tissue, it has been reported
that overweight patients with mixed dyslipidaemia who were administered the PPARβ/δ agonist
MBX-8025 for 8 weeks presented favourable trends in their body fat percentage, lean body mass and
waist circumference, although the differences did not reach statistical significance [30].
3.2. Dyslipidaemia
Atherogenic dyslipidaemia, often observed in patients with obesity, insulin resistance, metabolic
syndrome and type 2 diabetes mellitus, is a significant risk factor for cardiovascular disease. This
dyslipidaemia is characterized by the presence of low high-density lipoprotein (HDL) cholesterol
levels, elevated triglyceride (TG)-rich very low-density lipoprotein (VLDL) amounts and an increased
proportion of small and dense low-density lipoprotein (LDL) particles. It is presently accepted that
atherogenic dyslipidaemia is initiated by insulin resistance through the overproduction of TG-rich
VLDL [31]. Under conditions of insulin resistance, adipose tissue lipolysis is enhanced, leading
to an increase in plasma non-esterified FA (NEFA). The subsequent increase in the flux of NEFA
into the liver overcomes the oxidative capacity of hepatocytes and NEFA are then esterified for TG
production, causing hepatic steatosis and VLDL over secretion in the plasma [31]. Finally, in the
presence of hypertriglyceridemia, the cholesterol-ester content of LDL and HDL decreases, whereas
these lipoproteins are enriched in their TG content through the activity of cholesteryl ester transfer
protein. These TG-enriched particles are then hydrolysed by hepatic lipase, leading to the formation of
small, dense LDL and to the decrease in HDL-cholesterol levels [31].
PPARβ/δ agonists show a strong TG-lowering action in vivo. Given that the main factor
affecting hepatic TG secretion is FA availability, the hypotriglyceridaemic effect of PPARβ/δ activators
has been attributed, at least in part, to their ability to induce FA β-oxidation in the liver [32]
and other tissues [21,33] (Figure 2). In the liver, this role of PPARβ/δ involves the increased
expression of the genes involved in FA oxidation via amplification of the lipin 1/PPARγ-coactivator 1α
(PGC-1α)/PPARα signalling system and increased levels of the hepatic endogenous ligand for PPARα,
16:0/18:1-phosphatidylcholine [32]. Moreover, the increased FA β-oxidation caused by PPARβ/δ
activators might be due to the activation of AMP kinase (AMPK), probably through an increase in
the AMP:ATP ratio in hepatocytes [32]. Likewise, the effects of PPARβ/δ on the expression of several
genes (VldlR, ApoA5, ApoA4 and ApoC1) involved in lipoprotein metabolism can contribute to its
hypotriglyceridaemic effect [32,34]. In accordance with these effects of PPARβ/δ, mice deficient
in this receptor fed a high-fat diet (HFD) show increased plasma TG levels due to hepatic VLDL
overproduction. Moreover, these mice also exhibited reduced activity of the enzyme lipoprotein lipase,
which catalyses the hydrolysis of the TG component of circulating chylomicrons and VLDL.
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Figure  2.  Effects  of  PPARβ/δ  activation  in  dyslipidaemia.  PPARβ/δ  activation  ameliorates 
atherogenic  dyslipidaemia  by  reducing  the  amounts  of  very  low‐density  lipoprotein  (VLDL)‐
triglyceride (TG) and small dense low‐density lipoprotein (LDL) particles and increasing the levels 
of  high‐density  lipoprotein  (HDL)‐cholesterol.  PPARβ/δ  ligands  reduce  VLDL‐TG  by  increasing 
hepatic fatty acid (FA) oxidation, which decreases the availability of this lipid for TG synthesis and 
changing  the expression of  several apoproteins. PPARβ/δ  ligands  increase HDL‐cholesterol  levels 
by elevating the amounts of the main apopoproteins of these  lipoproteins (ApoA1 and ApoA2)  in 
the liver and raising the levels of ATP‐binding cassette A1 (ABCA1) in macrophages. Reduced LDL‐
cholesterol  levels  results  from  a  decrease  in  cholesterol  absorption  and  an  increase  in  faecal 
excretion that are mediated by PPARβ/δ activation. Blue arrow: increases. Red arrow: decreases. 
PPARβ/δ  agonists  also  increase  plasma HDL‐cholesterol  levels  and  reduce  LDL‐cholesterol 
and NEFA  levels  in  both  animal models  and  humans  [30,33–36].  The  increase  in  plasma HDL‐
cholesterol  levels following PPARβ/δ activation has been  linked to an  increased expression of the 
two major  apolipoproteins  of HDL,  ApoA1  and  ApoA2  [36],  in  the  liver.  In  addition,  PPARβ/δ 
activation  increases  the  expression  in macrophages  of  the  reverse  cholesterol  transporter, ATP‐
binding cassette A1 (ABCA1) [36,37], which is crucial for the formation of HDL particles through its 
transport  of  cholesterol  and  phospholipid  to  apolipoprotein  acceptors  in  the  bloodstream. 
Furthermore,  PPARβ/δ  agonists  also  regulate  the  expression  of  hepatic  phospholipid  transfer 
protein (Pltp), which regulates the size and the composition of HDL and plays an important role in 
controlling  plasma  HDL  levels  [38].  More  recently,  it  has  been  reported  that  the  absence  of 
intestinal PPARβ/δ abolishes  the ability of  its agonists  to  increase HDL‐cholesterol plasma  levels 
[22]. 
Regarding  the  reduction  in  LDL‐cholesterol  levels,  PPARβ/δ  agonists  have  been  shown  to 
decrease  the  efficiency  of  intestinal  cholesterol  absorption  possibly  by  reducing  the  intestinal 




The  assessment  of  PPARβ/δ  agonists  in  several  small‐scale  clinical  trials  mainly  for  the 
treatment of atherogenic dyslipidaemia has confirmed  that  these drugs reduce plasma TG  levels, 
increase  the amounts of HDL‐cholesterol and decrease  the  levels of small dense LDL particles  in 
Figure 2. Effects of PPARβ/δ activation in dyslipidaemia. PPARβ/δ activation ameliorates atherogenic
dyslipidaemia by reducing the amounts of very low-density lipoprotein (VLDL)-triglyceride (TG)
and small dense low-density lipoprotein (LDL) particles and increasing the levels of high-density
lipoprot in (HDL)-cholester l. PPARβ/δ ligands reduce VLDL-TG by increasing hepatic fatty acid (FA)
oxidation, which d crea es the availability of h s lipid for TG synthesis nd changing the expr ssion
of several apoproteins. PPARβ/δ ligands increase HDL-chol terol levels by elevating the amounts of
the main apopoproteins of these lipoproteins (ApoA1 and ApoA2) in the liver and raising the levels
of ATP-binding cassette A1 (ABCA1) in macrophages. Reduced LDL-cholesterol levels results from
a decrease in cholesterol absorption and an increase in faecal excretion that are mediated by PPARβ/δ
activation. Blue arrow: increases. Red arrow: decreases.
PPARβ/δ agonists a so crease plasma HDL-cholesterol levels d reduce LDL-cholesterol and
NEFA levels in both animal models and humans [30,33–36]. The incr ase in plasma HDL-cholesterol
levels following PPARβ/δ activation has been linked to an increased expression of the two major
apolipoproteins of HDL, ApoA1 and ApoA2 [36], in the liver. In addition, PPARβ/δ activation
increases the expression in macrophages of the reverse cholesterol transporter, ATP-binding cassette A1
(ABCA1) [36,37], which is crucial for the formation of HDL particles through its transport of cholesterol
and phospholipid to apolipoprotein acceptors in the bloodstream. Furthermore, PPARβ/δ agonists
also regulate the expression of hepatic phospholipid transfer protein (Pltp), which regulates the size
and the composition of HDL and plays an important role in controlling plasma HDL levels [38]. More
recently, it has bee report that the absen e of intestinal PPARβ/δ abolishe t e ability of its agonists
to increase HDL-cholesterol plasma levels [22].
Regarding the reduction in LDL-cholesterol levels, PPARβ/δ agonists have been shown to
decrease the efficiency of intestinal cholesterol absorption possibly by reducing the intestinal abundance
of the cholesterol absorption protein, Niemann-Pick C1-like 1 (NPC1L1) [39]. Furthermore, PPARβ/δ
activation also stimulates faecal excretion of cholesterol in mice, primarily by the two-fold increase
in trans-intestinal cholesterol efflux [40], a non-hepatobiliary-related route that transports cholesterol
from the blood to the intestinal lumen directly via enterocytes.
The assessment of PPARβ/δ agonists in several small-scale clinical trials mainly for the treatment
of atherogenic dyslipidaemia has confirmed that these drugs reduce plasma TG levels, increase
the amounts of HDL-cholesterol and decrease the levels of small dense LDL particles in humans,
indicating that treatment with these drugs initiates a transition towards a less atherogenic lipoprotein
profile [30,37,41–43].
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3.3. Type 2 Diabetes Mellitus
More than 90% of patients with type 2 diabetes mellitus are overweight or obese, since obesity
is associated with insulin resistance. Insulin resistance, which is defined as a defect in the ability
of insulin to drive glucose into its target tissues, predicts and precedes the development of type 2
diabetes mellitus [44]. However, patients with insulin resistance do not develop hyperglycaemia and
type 2 diabetes mellitus until the pancreatic β cells fail to secrete sufficient amounts of insulin to meet
the increased metabolic demand for this hormone. Adipose tissue expansion in obese individuals
releases increased amounts of NEFAs, hormones, pro-inflammatory cytokines and other factors that
contribute to the development of insulin resistance. Most of these molecules cause a chronic low-level
inflammation, which contributes to insulin resistance and type 2 diabetes mellitus [45].
PPARβ/δ agonists improve glucose tolerance and insulin sensitivity in animal models [20,46].
The antidiabetic effects of these drugs are exerted in different tissues. For instance, macrophage
infiltration into adipose tissue and polarization towards the pro-inflammatory M1 phenotype promotes
inflammation and correlates with the degree of insulin resistance [47]. As mentioned above, PPARβ/δ
activates polarization towards the anti-inflammatory M2 phenotype in macrophages [29] (Figure 3).
In accordance with this, myeloid-specific PPARβ/δ−/− mice show adipocyte dysfunction and insulin
resistance [29]. Interestingly, a link exists between metabolism and function in macrophages. Thus,
M2 macrophages require oxidative metabolism for their responses, whereas M1 macrophages depend
on aerobic glycolysis [48,49]. In fact, blocking oxidative metabolism leads to the polarization of
macrophages from the M2 to the M1 phenotype. Similarly, forcing oxidative metabolism in an
M1 macrophage potentiates the M2 phenotype [50,51]. Given that PPARβ/δ activation increases
β-oxidation in macrophages [52], this effect might also contribute to the polarization to the M2
phenotype caused by the agonists of this receptor. Macrophages also play a key function in
a specialized phagocytic process called efferocytosys [53] that contributes to promoting the resolution
of inflammation and PPARβ/δ activation enhances this process [53,54]. Since a defective efferocytosys
has emerged as a causal factor in the etiopathogenesis of atherosclerosis [55], the increase in this
process caused by PPARβ/δ activation might contribute to its beneficial effects in atherosclerosis.
Interleukin (IL)-6 is one of the inflammatory mediators released by adipose tissue that correlates
most strongly with obesity and insulin resistance, predicting the development of type 2 diabetes
mellitus [56]. PPARβ/δ activation prevents IL-6-induced insulin resistance by inhibiting the signal
transducer and activator of transcription 3 (STAT3) pathway in adipocytes, whereas this pathway is
over activated in PPARβ/δ-null mice compared to wild-type animals [57].
Skeletal muscle is the primary site of insulin resistance in obesity and type 2 diabetes mellitus
since it displays the highest level of insulin-stimulated glucose utilization [5]. Increased plasma
levels of saturated NEFAs, caused by the expansion of adipose tissue, promote inflammation and
insulin resistance through several mechanisms: the synthesis of FA-derived complex lipids such
as diacylglycerol and ceramides; the impairment of the function of cellular organelles (endoplasmic
reticulum [ER] stress and mitochondrial dysfunction); and the activation of pro-inflammatory pathways
through membrane receptors, such as toll-like receptor 4 (TLR4). PPARβ/δ activation the decrease in
insulin sensitivity by suppressing the FA-induced increase in diacylglycerol levels and the subsequent
activation of protein kinase C (PKC)θ and NF-κB by enhancing the expression of the genes involved in
FA oxidation via PGC-1α and by increasing AMPK phosphorylation [58,59]. Furthermore, PPARβ/δ
overexpression in the skeletal muscle of mice has been reported to promote the interaction between
PPARβ/δ and AMPK, which enhances glucose uptake, FA oxidation and insulin sensitivity [60].
PPARβ/δ agonists also prevent palmitate-induced ER stress in myotubes through a mechanism
involving AMPK activation [61]. Overall, it is believed that PPARβ/δ activation in skeletal muscle
produces changes that resemble the effects of exercise training [61], making it a potential candidate for
mimicking the effects of exercise to treat metabolic diseases [62].
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Figure 3. Effects of PPARβ/δ in type 2 diabetes mellitus. This figure depicts the effects of PPARβ/δ
ligands in adipose tissue, skeletal muscle, the liver and pancreatic β cells that contribute to the
attenuation of type 2 diabetes mellitus. In adipose tissue, PPARβ/δ activation switches macrophage
polarization towards the anti-inflammatory M2 phenotype and prevents IL-6-induced insulin resistance
by inhibiting STAT3. In skeletal muscle, PPARβ/δ ligands induce FA oxidation, reducing their
availability for the synthesis of deleterious complex lipids involved in inflammation and prevent
endoplasmic reticulum (ER) stress by activating AMPK. PPARβ/δ activation in hepatocytes blocks the
effects of IL-6 by inhibiting the STAT3 pathway through several mechanisms and increasing FGF21
levels. PPARβ/δ activators promote the beneficial effects of GLP-1 in the pancreas and enhance GSIS.ER,
endoplasmic reticulum; FA, fatty acid; GLP-1, glucagon-like peptide 1; GSIS, glucose-stimulated insulin
secretion; IL-6, interleukin 6; STAT3, signal transducer and activator of transcription 3. Blue arrow:
increases. Red arrow: decreases.
In the liver, IL-6 induces insulin resistance by activating STAT3-suppressor of cytokine signalling 3
(SOCS3) pathway [63]. We have previously reported that PPARβ/δ activation prevents the attenuation
of the insulin signalling pathway in human liver cells by preventing IL-6-induced STAT3 activation
through a mechanism that inhibits ERK1/2 phosphorylation and suppresses the reduction in
phospho-AMPK levels [64]. More recently, the inhibitory effect of PPARβ/δ on STAT3 was confirmed,
with a new mechanism described involving a T cell protein tyrosine phosphatase 45 (TCPTP45)
isoform [65]. According to this recent study, short-term PPARβ/δ activation prevents IL-6-induced
insulin resistance as a result of PPARβ/δ forming a complex with nuclear TCPTP45 and retaining it in
the nucleus, thereby deactivating the STAT3-SOCS3 signalling [65]. Fibroblast growth factor 21 (FGF21)
is a liver-derived circulating hormone that has emerged as an important regulator of glucose and lipid
metabolism, making it a promising agent for the treatment of insulin resistance and type 2 diabetes
mellitus [66]. Since PPARβ/δ activators increase the plasma levels of FGF21 in humans [67], some of
the antidiabetic effects of these drugs might be mediated by the increased levels of this protein.
β-cell failure, a result of the progressive decline in pancreatic β cell function and mass, impairs
insulin secretion and contributes to the development of type 2 diabetes mellitus [68]. PPARβ/δ
activation in the small intestine potentiates the production of glucagon-like peptide (GLP)-1, which
preserves β cell morphology and function, thereby increasing systemic insulin sensitivity [69]. This is
consistent with a recent study reporting that intestinal PPARβ/δ protects against diet-induced
obesity and insulin resistance [26]. Moreover, PPARβ/δ activation protects pancreatic β cells from
palmitate-induced apoptosis by upregulating the expression of the receptor for GLP-1 [70]. PPARβ/δ
agonists also increase mitochondrial oxidation in β cells, enhance glucose-stimulated insulin secretion
(GSIS) from pancreatic islets and protect GSIS from the adverse effects of prolonged FA exposure [71].
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In fact, PPARβ/δ is critical for the expression of the genes involved in mitochondrial function and
consequently ATP production, in β cells, which is required for GSIS [72].
3.4. Non-Alcoholic Fatty Liver Disease (NAFLD)
NAFLD encompasses a spectrum of liver disorders ranging from simple steatosis (non-alcoholic
fatty liver, NAFL) to non-alcoholic steatohepatitis (NASH) and liver fibrosis. It is closely linked to obesity
and metabolic syndrome, predisposing susceptible individuals to cirrhosis, hepatocellular carcinoma and
cardiovascular disease [73]. At present, there are no approved pharmacological therapies for NAFLD.
In animal models, long-term treatment with PPARβ/δ agonists attenuates hepatic steatosis by enhancing
FA oxidation, reducing lipogenesis and improving insulin sensitivity [74–77]. PPARβ/δ activation
and overexpression inhibit lipogenesis in hepatocytes by inducing the expression of insulin-induced
gene-1 (INSIG-1), an ER protein that blocks the activation of sterol regulatory element-binding protein-1
(SREBP-1), a pivotal transcription factor controlling lipogenesis in hepatocytes [77]. However, short
treatments with PPARβ/δ agonists might result in a transient increase in hepatic TG levels [78] but
without hepatotoxicity, since PPARβ/δ increases the number of monounsaturated FAs but reduces the
levels of saturated FAs [79]. In addition, PPARβ/δ might affect hepatic TG levels by regulating the
abundance of the VLDL receptor [80]. In humans, PPARβ/δ agonists reduce hepatic fat content and
elicit improvements in the plasma markers of liver function [30,33]. These and additional findings point
to PPARβ/δ, similarly to PPARα, as a master regulator of hepatic intermediary metabolism. During
fasting conditions, hepatic metabolism is programmed to oxidize FA and both, PPARα and PPARβ/δ
are thought to promote ketogenesis by inducing FGF21 [67] and the expression of genes involved in fatty
acid oxidation [81] in rodents. Interestingly, as mentioned before, PPARβ/δ activation in mice increases
the hepatic levels of the hepatic endogenous ligand for PPARα, 16:0/18:1-phosphatidylcholine, leading
to amplification of the PGC-1α-PPARα pathway [32], suggesting the presence of a cooperation between
both nuclear receptors in the regulation of hepatic metabolism.
The progression from NAFL to NASH involves the development of inflammation and signs of
hepatocellular damage [65]. Both the hepatic expression of inflammatory genes [74,76,82] and hepatic
ER stress [76], which contribute to the activation of inflammatory pathways, are reduced by PPARβ/δ
ligands. This hepatoprotective effect of PPARβ/δ ligands might also involve Kupffer cells, resident
liver macrophages that play a critical role in maintaining liver functions. Hematopoietic deficiency
of PPARβ/δ selectively impairs the alternative activation of Kupffer cells in obese mice, leading
to reduced oxidative metabolism and hepatic dysfunction [83]. Additional studies are required to
conclusively determine the effects of PPARβ/δ agonists on liver fibrosis due to the inconsistent results
currently reported in the literature [17,84].
4. Safety of PPARβ/δ Agonists
Despite the promising data of PPARβ/δ agonists in metabolic disorders in preclinical studies,
the discovery that mice treated with GW501516 developed adenocarcinoma [85] halted further
development of this drug and undermined the potential use of these drugs in human therapeutics.
However, subsequent attempts to assess the role of PPARβ/δ in cancer have demonstrated that
this receptor both inhibits and promotes tumorigenesis, as it has been extensively reviewed
previously [10,86,87], becoming one of the most controversial effects of PPARβ/δ. The conflicting
results about PPARβ/δ in cancer might indicate that the activity of this receptor in cancer development
is influenced by the mutational status of the tumour cell and the tumour environment [10]. Moreover,
it has been proposed that the high-level expression of PPARβ/δ in normal cells suggest an antitumour
effect for this receptor but the reduction in its expression or the presence of endogenous antagonists or
inverse agonists might lead to a protumorigenic role for PPARβ/δ [86].
Although there are only a few clinical trials assessing the safety of PPARβ/δ agonists, the
administration of these drugs to humans seems to be safe and generally well-tolerated, at least for the
short periods evaluated [30]. Thus, no study subjects were withdrawn because of adverse effects from
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a study evaluating the administration of seladelpar for 8 weeks to dyslipidaemic overweight patients
at doses showing beneficial metabolic effects [30]. Treatment with this PPARβ/δ agonist slightly
but significantly decreased red blood cell count, haemoglobin and haematocrit. In a more recent
study, the effect of seladelpar was assessed in patients with primary biliary cholangitis [88]. Drug
treatment for 12 wk. elicited anti-cholestatic effect but three patients showed rapidly reversible alanine
aminotransferase elevations and the study was interrupted before completion. The authors of the
study suggest that this effect might be specific for these patients with primary biliary cholangitis due to
the biliary excretion of seladelpar ant its metabolites, leading to increased hepatic drug concentrations.
5. Conclusions
Over the past 20 years, a substantial body of preclinical evidence has demonstrated that PPARβ/δ
activation is a promising therapeutic strategy for treating obesity-associated co-morbidities. This has
led to the assessment of PPARβ/δ agonists in clinical trials, although these studies on the efficacy
and safety of PPARβ/δ agonists in humans are scarce. Safety issues have been raised regarding the
role of PPARβ/δ ligands in carcinogenesis [87]. However, there are conflicting findings on the role of
PPARβ/δ as a tumour suppressor or tumour promoter [87], the latter being mostly observed in animal
models. Further studies are required to obtain conclusive data on the role of PPARβ/δ in human
cancer given that although mouse models are invaluable tools for investigating basic tumour biology,
they show significant limitations when compared to human beings. For instance, PPARs are expressed
at lower levels in human than in rodent cells and gene expression is also regulated differently by
PPARs in human and rodent cells [9]. These differences might explain why long-term treatment with
PPARα ligands have been shown to induce carcinogenesis in rodents but carcinogenesis has not been
observed in humans treated with the PPARα agonists fibrates for dyslipidaemia over the decades [89].
However, this needs to be studied for PPARβ/δ too.
In summary, although further studies are required to confirm the safety of PPARβ/δ ligands, these
drugs have demonstrated that modulation of PPARβ/δ activity shows efficacy in preclinical studies
and in a few clinical trials in the treatment of dyslipidaemia, type 2 diabetes mellitus and NAFLD.
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